News Network: Bladder Cancer at ASCO GU 2026

Leslie K. Ballas, MD, discusses the background and design for the phase 2 BRIGHT trial, evaluating a risk-adapted bladder preservation strategy in MIBC.

Robert S. Svatek, MD, MSCI, highlights some of the greatest unmet needs in the non–muscle invasive bladder cancer space.

As immunotherapy and antibody-drug conjugates move earlier in treatment, questions about sequencing therapies are emerging.

Sophia C. Kamran, MD, highlights some of the key bladder cancer trials presented at ASCO GU 2026 from the perspective of a radiation oncologist.

Laura Bukavina, MD, MPH, MSc, sat down to discuss the emerging role of ctDNA in guiding treatment decisions for patients with muscle-invasive bladder cancer, drawing on findings from the RETAIN and RETAIN 2 trials.

According to Sophia Kamran, MD, innovation in bladder cancer is expanding treatment options and patient-centered care.